Growth-hormone secretagogues

A selective growth-hormone secretagogue prized for its clean profile: it stimulates GH release with minimal effect on cortisol, prolactin or appetite, which is why it became a staple of GH-focused protocols. Formal outcome trials for physique and recovery goals haven't been run.

with DAC, Mod GRF (1-29)

A GHRH analogue that amplifies the body's natural GH pulses, classically paired with ipamorelin to hit both release pathways at once. Pharmacology studies show substantial, sustained GH and IGF-1 elevation, especially with the DAC variant; physique outcome trials are lacking.

GHRH (1-29)

A GHRH analogue with decades of clinical history — first as a diagnostic for GH deficiency, now widely prescribed through longevity and wellness clinics. Its GH-releasing effect in humans is well documented; modern anti-ageing outcome data are thinner.

Egrifta

A GHRH analogue approved to reduce excess abdominal fat in HIV-associated lipodystrophy. Off-label physique use is not supported by that approval.

Ibutamoren

An orally active ghrelin-receptor agonist that raises GH and IGF-1. Investigated in trials but not approved; popular for physique use.

The most potent of the classic growth-hormone-releasing peptides, with research interest extending to cardioprotective effects. Its trade-offs are known: it can raise cortisol/prolactin and receptors desensitise with continuous use, which shapes how the community cycles it.

Growth Hormone Releasing Peptide-6

One of the original growth-hormone-releasing peptides, distinctive for the strong hunger response that makes it popular in appetite- and mass-focused phases. GH release is its established effect; formal physique outcome trials haven't been run.

Pralmorelin

A growth-hormone-releasing peptide with genuine clinical pedigree — approved in Japan as the diagnostic agent pralmorelin. It releases more GH than GHRP-6 with less of the hunger effect, which is its niche in the community.

Long R3 IGF-1

A modified, long-acting form of IGF-1 — one of the most anabolic signalling molecules in the body — engineered to stay active far longer than the native hormone. That potency is the appeal in bodybuilding and also the risk: hypoglycaemia and indiscriminate tissue growth are real, and it is WADA-prohibited.

Mechano Growth Factor, IGF-1Ec, Pegylated MGF

A pegylated form of mechano growth factor — the IGF-1 splice variant muscle produces in response to mechanical stress, which activates satellite cells for repair. That biology is real and well studied; product use in humans hasn't been trialled, and it is WADA-prohibited.

FS-344

A form of follistatin, the body's natural myostatin blocker. Gene-therapy and animal studies produced dramatic muscle growth — the famous 'double-muscled' phenotypes — which is the draw; whether an injected peptide product reproduces any of that in humans is untested, and it falls under WADA's myostatin-related prohibitions.